Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
NCT02307812 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2025-01-09
Summary
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the ATU.
Conditions
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
Interventions
- DRUG
-
Administered intravenously (IV)
- DRUG
-
Administered IV
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma
NCT01170663 ·Status: COMPLETED ·Phase: PHASE3
-
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
NCT00917384 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer
NCT02443324 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas
NCT01253525 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
NCT02539225 ·Status: COMPLETED ·Phase: PHASE2
-
Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis
NCT02628951 ·Status: COMPLETED ·Phase: PHASE2
-
Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
NCT03141034 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer
NCT02359058 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer
NCT01983878 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Data of Paclitaxel and Ramucirumab Compared to Other Treatment Regimens in Advanced Gastric Cancer
NCT06666582 ·Status: COMPLETED
-
Phase II Study of Ramucirumab With Chemotherapy in Patients With Metastatic Gastroesophageal Junction and Gastric Cancer
NCT02726399 ·Status: TERMINATED ·Phase: PHASE2
-
Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma
NCT04604132 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
NCT04660760 ·Status: RECRUITING ·Phase: PHASE2
-
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
NCT04499924 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Real-world Data (RWD) of Ramucirumab Plus Paclitaxel
NCT04915807 ·Status: UNKNOWN
-
Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
NCT02317991 ·Status: COMPLETED ·Phase: PHASE2
-
Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma
NCT03966118 ·Status: UNKNOWN ·Phase: PHASE2
-
Ramucirumab Plus TAS-102 in Patients With Advanced or Metastatic Gastric Adenocarcinoma or the Gastroesophageal Junction
NCT04517747 ·Status: COMPLETED ·Phase: NA
-
Rucaparib Plus Ramucirumab With or Without Nivolumab in Advanced Gastric and Esophageal Adenocarcinoma
NCT03995017 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
NCT03766607 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
NCT02999295 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma
NCT06043427 ·Status: RECRUITING ·Phase: PHASE2
-
An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Therapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT03704077 ·Status: WITHDRAWN ·Phase: PHASE2
-
Paclitaxel and Irinotecan in Advanced Gastric Cancer
NCT01136031 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
NCT06038578 ·Status: RECRUITING ·Phase: PHASE2